Michael Burkes Brophy Sells 499 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 499 shares of the company’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $107.40, for a total transaction of $53,592.60. Following the sale, the chief financial officer now directly owns 77,418 shares of the company’s stock, valued at $8,314,693.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, July 1st, Michael Burkes Brophy sold 4,983 shares of Natera stock. The shares were sold at an average price of $108.37, for a total transaction of $540,007.71.
• On Wednesday, May 1st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The stock was sold at an average price of $93.97, for a total transaction of $175,348.02.
• On Monday, April 29th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The shares were sold at an average price of $93.14, for a total value of $115,307.32.
• On Thursday, April 25th, Michael Burkes Brophy sold 705 shares of Natera stock. The shares were sold at an average price of $89.55, for a total value of $63,132.75.

Natera Stock Up 1.0 %

Shares of NTRA traded up $1.01 during trading hours on Tuesday, hitting $106.52. 895,366 shares of the company were exchanged, compared to its average volume of 1,329,804. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.98 and a current ratio of 4.12. The company has a market cap of $13.08 billion, a PE ratio of -34.14 and a beta of 1.48. The firm’s 50 day moving average is $109.29 and its 200-day moving average is $91.89. Natera, Inc. has a 52 week low of $36.90 and a 52 week high of $117.23.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, May 9th. The medical research company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.16. Natera had a negative return on equity of 49.72% and a negative net margin of 30.24%. The firm had revenue of $367.70 million during the quarter, compared to analysts’ expectations of $316.31 million. During the same quarter in the prior year, the business earned ($1.23) earnings per share. The company’s revenue was up 52.1% on a year-over-year basis. On average, equities research analysts forecast that Natera, Inc. will post -2.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

NTRA has been the subject of several research analyst reports. Jefferies Financial Group initiated coverage on Natera in a research note on Monday, June 3rd. They issued a “buy” rating and a $142.00 price objective for the company. Craig Hallum initiated coverage on shares of Natera in a report on Monday, April 8th. They set a “buy” rating and a $117.00 price target for the company. Piper Sandler upped their price objective on shares of Natera from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Tuesday, May 14th. Sanford C. Bernstein upgraded shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 target price for the company in a research report on Friday, April 5th. Finally, BTIG Research boosted their price target on shares of Natera from $100.00 to $125.00 and gave the company a “buy” rating in a report on Monday, May 13th. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, Natera has a consensus rating of “Moderate Buy” and an average price target of $101.19.

Institutional Trading of Natera

Several large investors have recently modified their holdings of NTRA. Norges Bank acquired a new position in Natera during the 4th quarter worth $83,970,000. Perceptive Advisors LLC increased its stake in shares of Natera by 289.7% in the fourth quarter. Perceptive Advisors LLC now owns 850,225 shares of the medical research company’s stock worth $53,258,000 after purchasing an additional 632,047 shares during the period. Vanguard Group Inc. lifted its position in shares of Natera by 5.7% during the 4th quarter. Vanguard Group Inc. now owns 10,971,895 shares of the medical research company’s stock worth $687,280,000 after purchasing an additional 588,147 shares during the last quarter. First Light Asset Management LLC boosted its stake in Natera by 295.9% during the 1st quarter. First Light Asset Management LLC now owns 656,708 shares of the medical research company’s stock valued at $60,063,000 after purchasing an additional 490,822 shares during the period. Finally, Farallon Capital Management LLC grew its holdings in Natera by 13.0% in the 1st quarter. Farallon Capital Management LLC now owns 3,927,683 shares of the medical research company’s stock valued at $359,226,000 after buying an additional 452,800 shares during the last quarter. 99.90% of the stock is owned by institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.